MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):26-30. doi: 10.15585/mmwr.mm7101e1.
COVID-19 vaccines are recommended during pregnancy to prevent severe maternal morbidity and adverse birth outcomes; however, vaccination coverage among pregnant women has been low (1). Concerns among pregnant women regarding vaccine safety are a persistent barrier to vaccine acceptance during pregnancy. Previous studies of maternal COVID-19 vaccination and birth outcomes have been limited by small sample size (2) or lack of an unvaccinated comparison group (3). In this retrospective cohort study of live births from eight Vaccine Safety Datalink (VSD) health care organizations, risks for preterm birth (<37 weeks' gestation) and small-for-gestational-age (SGA) at birth (birthweight <10th percentile for gestational age) after COVID-19 vaccination (receipt of ≥1 COVID-19 vaccine doses) during pregnancy were evaluated. Risks for preterm and SGA at birth among vaccinated and unvaccinated pregnant women were compared, accounting for time-dependent vaccine exposures and propensity to be vaccinated. Single-gestation pregnancies with estimated start or last menstrual period during May 17-October 24, 2020, were eligible for inclusion. Among 46,079 pregnant women with live births and gestational age available, 10,064 (21.8%) received ≥1 COVID-19 vaccine doses during pregnancy and during December 15, 2020-July 22, 2021; nearly all (9,892; 98.3%) were vaccinated during the second or third trimester. COVID-19 vaccination during pregnancy was not associated with preterm birth (adjusted hazard ratio [aHR] = 0.91; 95% CI = 0.82-1.01). Among 40,627 live births with birthweight available, COVID-19 vaccination in pregnancy was not associated with SGA at birth (aHR = 0.95; 95% CI = 0.87-1.03). Results consistently showed no increased risk when stratified by mRNA COVID-19 vaccine dose, or by second or third trimester vaccination, compared with risk among unvaccinated pregnant women. Because of the small number of first-trimester exposures, aHRs for first-trimester vaccination could not be calculated. These data add to the evidence supporting the safety of COVID-19 vaccination during pregnancy. To reduce the risk for severe COVID-19-associated illness, CDC recommends COVID-19 vaccination for women who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might become pregnant in the future (4).
COVID-19 疫苗的接种建议在妊娠期间进行,以预防严重的孕产妇发病率和不良的出生结局;然而,孕妇的疫苗接种覆盖率一直很低(1)。孕妇对疫苗安全性的担忧是她们在怀孕期间接受疫苗接种的一个持续障碍。之前关于孕产妇 COVID-19 疫苗接种和出生结局的研究受到样本量小(2)或缺乏未接种疫苗的对照组(3)的限制。在这项来自八个疫苗安全数据链接(VSD)医疗保健组织的活产回顾性队列研究中,评估了妊娠期间 COVID-19 疫苗接种(接受≥1 剂 COVID-19 疫苗)后早产(<37 周妊娠)和出生时小于胎龄儿(SGA)的风险(出生体重<妊娠龄第 10 百分位)。比较了接种疫苗和未接种疫苗的孕妇的早产和 SGA 风险,同时考虑了疫苗暴露的时间依赖性和接种疫苗的倾向。符合条件的是在 2020 年 5 月 17 日至 10 月 24 日期间估计开始或末次月经的单胎妊娠。在 46079 名有妊娠和胎龄可用的孕妇中,有 10064 名(21.8%)在妊娠期间和 2020 年 12 月 15 日至 2021 年 7 月 22 日期间接受了≥1 剂 COVID-19 疫苗;几乎所有(9892 人;98.3%)都是在第二或第三孕期接种的。妊娠期间接种 COVID-19 疫苗与早产无关(调整后的危险比[aHR] = 0.91;95% CI = 0.82-1.01)。在 40627 名有出生体重可用的活产中,妊娠期间接种 COVID-19 疫苗与出生时 SGA 无关(aHR = 0.95;95% CI = 0.87-1.03)。结果一致表明,与未接种疫苗的孕妇相比,按 mRNA COVID-19 疫苗剂量、第二或第三孕期接种疫苗分层时,风险没有增加。由于第一孕期暴露的数量较少,因此无法计算第一孕期接种疫苗的 aHR。这些数据增加了支持 COVID-19 疫苗在妊娠期间安全的证据。为了降低与严重 COVID-19 相关疾病的风险,CDC 建议对孕妇、近期孕妇(包括哺乳期)、目前正在尝试怀孕或将来可能怀孕的妇女接种 COVID-19 疫苗(4)。